Binder Gauntlet
AnthropicOfficialPublished by Anthropic
- Skill
- Workflow
- Science and research
- Apache-2.0
- Low risk
- Has scripts
AutoGineer summary
Written by AutoGineer from the skill’s own files, not by the author
Binder-gauntlet provides a structured computational protocol to validate de novo designed protein binders and miniproteins. It moves beyond initial structure-predictor confidence scores by implementing independent re-prediction, pose agreement checks, developability profiling, and specificity testing. The skill is designed to be used iteratively throughout a design campaign to steer selection, filter candidates, and generate a final validation dossier for laboratory transition.
What it does
- Validates binding claims using independent structure predictors and pose agreement metrics.
- Profiles chemical and physical developability, including aggregation risks and surface charge.
- Checks for specificity and cross-reactivity against paralogs and orthologs.
- Assesses native context, including glycosylation sites and domain architecture.
- Generates a structured validation dossier and per-design data table.
- Provides a sequence-level profiling script for identifying liability motifs.
When to use it
- When you need to validate binder designs beyond initial structure-predictor confidence.
- At each selection round of a design campaign to filter and steer development.
- When preparing a validation dossier for leads before laboratory synthesis.
- When you need to check for sequence liabilities, specificity, or developability flags.
Advantages
- Promotes objective decision-making by using independent predictors and controls.
- Enables early identification of design liabilities to save time and resources.
- Provides a standardized reporting format for design campaigns.
- Target-agnostic and tool-agnostic, allowing integration with existing local predictors.
Usage examples
- “Validate these binder designs.”
- The agent runs the gauntlet protocol, including independent re-prediction, pose agreement checks, and developability profiling, resulting in a validation dossier.
- “Check developability and sequence liabilities for this set of binders.”
- The agent uses the sequence profiling script to identify motifs, charge patches, and aggregation-prone stretches, reporting them in a structured table.
- “Which of these designs should go to the lab?”
- The agent evaluates the designs against the consensus rule and developability criteria, providing a ranked list with justifications for those kept and those set aside.
- “Create a validation dossier for my top binder leads.”
- The agent compiles the results from the binding validation, specificity panel, and developability checks into a markdown dossier based on the provided template.
Install
Download the skill as a ZIP:
https://autogineer.com/agent-skills/anthropics/binder-gauntlet/downloadUnzip it into the cross-client skills folder of your project:
mkdir -p .agents/skills && unzip binder-gauntlet.zip -d .agents/skills
Documentation by Anthropic
Binder gauntlet: validate and profile designed binders before anyone orders DNA
A structure predictor's interface confidence is the field's standard first filter, and it is only that. This skill is the rest of the computational diligence a protein-engineering or pharma team expects to see next to a table of designed binders: (A) evidence the binding claim survives checks the design loop did not optimise against, with controls; (B) a developability profile of each design; (C) an honest dossier that says what was not checked. It is target-agnostic and tool-agnostic — use whatever predictors and utilities are installed — but names common open tools and literature thresholds (see references/thresholds.md). Budget it explicitly: time one complex prediction per predictor and multiply — A1 for 30 designs × 2 predictors × 3 seeds is ≈180 complex predictions plus the monomer refolds and controls; A6–A9 on 10 leads roughly doubles that; part B is CPU-minutes.
Before you start
Script:
${CLAUDE_SKILL_DIR}/scripts/sequence_profile.py(standard library only) turns one or many sequences (a FASTA file, or--seq) into Part B's sequence-level table: size, pI and net charge, GRAVY, A280 measurability, cysteines, liability motifs with their positions, hydrophobic and charged windows, candidate protease sites; one row per design, CSV or--json. Run it on the shortlist every round instead of re-deriving the motif rules. First use in a new environment:python3 "${CLAUDE_SKILL_DIR}/scripts/sequence_profile.py" --self-testshould end "self-test passed".Where to write: a working folder in the user's directory, for example
gauntlet/<target>/with one sub-folder per round. Never write into the skill's folder.References:
references/thresholds.md(where every pass mark comes from),references/developability-checks.md(how to compute each Part B item),references/dossier-template.md(Part C),references/honest-limits.md(the sentences to use).On a cluster: where GPU work is dispatched as Kubernetes or Slurm jobs rather than run in the session, every structure-prediction run in Part A (complex re-predictions, monomer refolds, co-folds, the controls included) goes out as a batch job the way the session submits its other GPU work; Part B, the superpositions and the write-up stay in the session.
Principles
Independence. A check only adds evidence if the design loop did not optimise against it. Prefer predictors, seeds and physics terms outside your objective; say which checks are and are not independent.
Same pipeline for controls and designs. Every validation protocol is first run on positive and negative controls; report their numbers beside the designs'. A pipeline that cannot separate a known binder from a scrambled sequence is not evidence.
Not run ≠ passed. Anything you did not check is listed as not checked, with the reason.
Pass/fail only where the literature gives a threshold; otherwise report values against references. There is no validated computational developability gauntlet for miniproteins (antibody rules such as TAP do not transfer); show descriptors, compare to reference proteins if available, do not invent cut-offs.
Reject in the open. Candidates dropped on this evidence are part of the deliverable, with the reason.
Run it in the loop, not only at the end
These checks are for steering design, not just for documenting it. At every selection or refinement round, run the cheap ones on the current shortlist and use the results to decide what to keep, drop, mutate or redesign: sequence liabilities (above all labile motifs inside the interface), A280 measurability, pI and charge patches, hydrophobic patch on the free (non-interface) face, low-complexity or poly-residue runs, a self-association co-fold, designability/sequence recovery (A8, B1–B4, B7, B8 — minutes per round), plus an out-of-objective re-prediction with pose agreement, a monomer refold and the partner-superposition blocker test on the current top N (A1, A2, A5 — N × predictors × seeds complex predictions; time it as in the budget note above). Reserve the expensive checks — the full paralog/ortholog/decoy panel (A6), binding-dead mutants (A7), full-length-target refolds (A9), any MD (A10) — for leads before the final pick. Run the controls (A3) early, and again through each protocol the first time you use it, so every later number has a reference. Keep a running "set aside, and why" log from the first round; it becomes dossier topic 8. A liability found in a final candidate costs a redesign or a caveat; the same liability found at round one costs nothing. The dossier is the record of this steering, not the goal. One trade-off to manage (Principle 1): a predictor you select on joins your objective, so state the A4 rule before the first round, hold at least one predictor or protocol back for the final pass, and say in dossier topic 1 which checks steered selection and which stayed independent.
Part A — Binding-validation gauntlet (per design unless noted)
A1. Out-of-objective re-prediction and pose agreement. Re-predict each binder–target complex from sequence with at least one predictor not used in design or scoring — two if you have them — (e.g. AF2-multimer with target template ± initial guess, Boltz, Chai, Protenix/AF3-class, or single-sequence predictors where they support complexes), several seeds each. Record interface confidence (ipTM, interface pAE, ipSAE) and agreement with YOUR designed pose (DockQ, interface RMSD, binder RMSD after target superposition). Literature pass marks: interface pAE < 10; DockQ ≥ 0.49 "medium", ≥ 0.23 "acceptable"; binder Cα RMSD to design ≲ 2 Å (the pAE < 10 mark is calibrated for AF2 initial-guess; for other predictors report the value beside the controls' values rather than applying 10 as a pass line). A confident prediction in a different pose is a failure, not a pass. If only one independent predictor is available, run it with more seeds and label section 1 "single-predictor"; if none is, say so and report A2/A3/A5/A9 with the design-time predictor, marked not independent. A2. Monomer refold. Fold the binder alone (no target); require high pLDDT (> 80) and RMSD to the designed monomer ≲ 1–2 Å (≤ 3.5 Å bound-vs-unbound is BindCraft's filter). Flag fold-on-binding designs explicitly. A3. Controls through the identical protocol. Positives: a natural partner or known binder of the target extracted from a deposited complex if one exists (and an engineered high-affinity variant if public). Negatives: composition-preserving scrambles of several designs; a well-folded unrelated protein of similar size; and a decoy target (fold designs against an unrelated protein of the same fold class as the target). Report the score distributions and where each design falls; a design that scores with the negatives fails this check. A4. Consensus rule. State a rule before looking (e.g. "every independent predictor you ran — at least one, held back from selection — reproduces the designed pose at DockQ ≥ 0.49 and its interface confidence is in the range of the positive controls") and apply it uniformly; note that once used for selection it is no longer an independent check. A5. Function/epitope test by superposition. Superpose the natural partner's complex onto each predicted design complex; report steric clash with the partner and fraction of the partner's footprint covered → "predicted blocker: yes/no". Footprint overlap alone is weaker than clash. A6. Specificity and cross-reactivity panel (when sequences are available or can be staged): co-fold each design against the target's closest human paralogs and same-family domains and 1–2 unrelated same-fold decoys (want low confidence), and against mouse/cynomolgus orthologs (cross-reactivity is usually WANTED for animal models — report it as such). Co-folding confidence discriminates on/off-target only roughly; say so. A7. Binding-dead control mutants. For the top designs, propose 2–3-residue hotspot knockouts or charge reversals at the designed interface and re-predict; expect confidence/pose to collapse. Single-Ala changes rarely move co-folding scores — do not present this as a ΔΔG scan (that needs Rosetta/FoldX). Output: a named binding-dead mutant per lead for the lab. A8. Self-association. Co-fold two copies of each binder; a confident homodimer, especially one burying the binding face, is a flag (designed binders have turned out dimeric by SEC-MALS). A9. Native-context checks. From the target's UniProt entry: N-glycosylation sequons and annotated glycosites, disulfides, natural variants and isoform boundaries near the footprint — a design made against a bare, truncated crystal construct can target a surface that is glycan-covered or absent on the cell. Re-predict leads against the full extracellular region (or full domain architecture), not just the truncated construct you designed against, and check approach direction relative to the membrane/other domains. A10. Pose persistence. Across seeds, predictors and (optionally) short MD, report interface-contact persistence and pose RMSD spread; treat MD as a red-flag screen only — there is no published evidence we know of that it raises hit rates beyond A1-type filters. A11. Physics-lite interface metrics (label uncalibrated if no Rosetta/FoldX): buried SASA, shape complementarity, interface H-bonds/salt bridges, buried unsatisfied polar atoms, interface hydrophobic fraction.
Part B — Developability profile (CPU; per design)
See references/developability-checks.md for motif lists and how to compute each item with biopython/freesasa/DSSP. B1. Chemical liabilities with solvent exposure and interface membership: deamidation (NG ≫ NS > NT/NN), Asp isomerisation (DG, DS), Asp-Pro, exposed Met/Trp (oxidation), N-X-S/T sequons, free Cys, N-terminal Gln. B2. Charge: pI, net charge at pH 7.4, largest positive and negative surface patches; interface His count (pH sensitivity). B3. Hydrophobic surface: largest hydrophobic patch and a SAP-like score, reported separately for the binding face and the rest of the surface (the interface may be hydrophobic; the free surface should not be). B4. Aggregation-prone stretches (sliding-window hydrophobicity/β-propensity heuristic; a dedicated predictor such as Aggrescan3D/CamSol/TANGO if installed and licensed where required) and low-complexity/poly-ion runs. B5. Protease exposure: canonical trypsin/chymotrypsin/Asp-N sites that sit in loops with high SASA. B6. Stability proxies: monomer pLDDT, design-vs-refold RMSD, inverse-folding/LM log-likelihood, helix capping/buried polar sanity; note de novo miniproteins are typically hyperstable (Tm > 70–90 °C) so this is a sanity check, not a ranking. B7. Designability: sequence recovery of the designed backbone by an inverse-folding model and how many alternative sequences refold to it. B8. Format and manufacturability: which terminus is solvent-exposed and ≥ 15–20 Å from the interface (tag / Fc / albumin-binder attachment); expression host implied (Cys-free, no glycosylation → E. coli); A280 measurability (Trp/Tyr present?); gene-synthesis complexity of a codon-optimised gene (GC%, repeats, homopolymers); intended therapeutic/imaging format and its PK implication — an unmodified protein < 30–50 kDa is renally filtered (half-life of order minutes–hours); half-life comes from format (Fc, albumin binding, PEG/polypeptide fusion), not sequence. Do not report a "predicted PK" beyond this. B9. Immunogenicity: if an HLA-II epitope predictor is available, report predicted epitope density vs reference proteins; otherwise list it under "not checked". "Humanness" is undefined for de novo sequences; aggregation and epitope content are the computable levers; the real assessment is in vitro. B10. What must go to the lab regardless: expression/solubility/SEC, affinity and kinetics, specificity panel, Tm, protease/serum stability, structure of the complex, in-vitro immunogenicity, any PK.
Part C — Reporting
Write a markdown dossier covering these nine topics (template: references/dossier-template.md): (1) binding evidence beyond the objective + controls + consensus call; (2) function/blocker; (3) specificity and species cross-reactivity; (4) robustness (pose persistence, self-association, refold-alone; binding-dead mutants for leads); (5) native context; (6) developability per design; (7) interface metrics (uncalibrated); (8) candidates set aside and why; (9) not checked and why. Plus one per-design CSV keyed by the binder sequence, so rows can be joined to whatever table lists the designs. Use the limits language in references/honest-limits.md verbatim or close to it: co-folding models share training data, so agreement is correlated evidence; controls show the pipeline is not trivially fooled, not that designs bind; confidence filters raise lab hit rates but do not predict affinity; developability descriptors are shown against references, not as pass/fail.
Order of work when time is short
Controls first (A3), and through each new protocol as it is introduced → at each design round: B1–B4, B7, B8 and A8 on the shortlist (minutes) plus A1/A2/A5 on the current top N, dropping or redesigning on the results → before the final pick: complete A1/A2 on everything still kept (including the predictor held back from selection) and apply the A4 rule, then A9 and A6/A7 on the leads → the remaining items (A10, A11, B5, B6, B9) → write up, always leaving time for topic (9). If you only discover this skill at the end, run it in the listed order on the final set and say in the dossier that it was applied post hoc.
Files
- ATTRIBUTION.mdAdded by AutoGineer874 B
- DECLARED-USE-CASE.md5.4 KiB
- LICENSE.txt10.0 KiB
- README.md35.9 KiB
- SKILL.md14.6 KiB
- TOOLS.md.example3.5 KiB
- backtests.md26.9 KiB
- cluster/README.md9.8 KiB
- cluster/gpu-job.example.yaml3.1 KiB
- cluster/workspace.example.yaml2.2 KiB
- references/developability-checks.md6.9 KiB
- references/dossier-template.md3.7 KiB
- references/honest-limits.md1.9 KiB
- references/thresholds.md6.9 KiB
- rubric.md15.3 KiB
- sample/README.md7.5 KiB
- sample/fetch-sample.shScript2.9 KiB
- sample/ground-truth.yaml7.2 KiB
- scripts/sequence_profile.pyScript12.8 KiB
- steps.md6.3 KiB
README.md
Binder Gauntlet: design and check de novo miniprotein binders
From a public target structure to a scored, checked design panel
0. Quickstart
Run your first design panel on a public sample target. You need Claude Code on a machine with a GPU, and the design tools from section 4 installed.
1. Install the skill. In Claude Code, run:
/plugin marketplace add anthropics/life-sciences
/plugin install binder-gauntlet@life-sciences2. Make a working folder and fetch the sample target. In a terminal, run:
git clone https://github.com/anthropics/life-sciences ~/life-sciences
mkdir ~/binder-run && cd ~/binder-run
sh ~/life-sciences/binder-gauntlet/sample/fetch-sample.sh
cp ~/life-sciences/binder-gauntlet/TOOLS.md.example TOOLS.md3. Fill in TOOLS.md. Tell Claude how to call each tool on your machine. This is the only file you write.
4. Check your setup. Start Claude Code in ~/binder-run and paste the setup check from section 7, step 2. Fix anything it reports.
5. Run the design. Paste the design brief from section 7, step 3. A first run takes about an hour on one GPU.
6. Review the results. Open report.md, designs.csv and dossier.md. Section 9 explains what good looks like and what to check by hand.
1. Aim
This guide takes you from a target structure to a shortlist of binder designs that is ready for design review.
You start with one target domain that has a public structure. You finish with two things:
A panel of about 30 de novo miniprotein designs of 50 to 120 residues. Each design comes with:
its sequence
a model of the designed complex
the site it targets and the reason for choosing that site
interface-confidence scores from at least two structure-prediction programs
a check that the programs agree on the pose
a structural-cluster label
A validation dossier. The dossier contains:
the same screen, run on known binders and non-binders of the target
a developability profile of every design, shown against reference proteins
the candidates you set aside, and why
a list of what you did not check
You can trace every number to the program that produced it. You can then take the shortlist to the people who will express and assay it.
2. Who it is for
This guide is for protein engineers, computational biologists and structural biologists in discovery groups. These readers already know what a binder campaign involves. They want to run the full design, screen and check loop, with the reasoning written down.
You should be able to:
read a protein structure
interpret ipTM, pLDDT and interface predicted-aligned-error scores
judge the result, because a confident prediction does not prove that a design binds
This guide does not teach protein design.
You also need:
GPU compute that you control. One GPU machine is enough for the first run. To scale out, use a Kubernetes namespace or a Slurm partition with GPUs.
Someone who can install the tools. This person installs open-source structure-prediction and design tools on the machine or in a container image (section 4).
This guide does not suit:
anyone who wants a sequence to order without reviewing the models
targets with no experimental structure of the domain of interest
antibody or peptide design, which use different tools
any target or purpose outside your declared use case (section 11)
3. Surface
Start with Claude Code and the binder-gauntlet skill on a GPU machine you control (Route A in section 7). This can be a workstation, a cloud instance in your own tenant, or an interactive session on a cluster node.
Claude Code manages the loop. It chooses the site, runs the tools, reads the results, applies the checks and writes the report. The design and prediction tools run on the same machine, so you have nothing to set up between the session and the GPU.
The binder-gauntlet skill adds validation and developability checks that steer selection during the run.
You need only Claude Code and the open-source tools. Your compute, files and designs stay inside your own infrastructure. We developed and tested the method on this setup, so use it for your first run.
Begin with one session, one GPU and a fixed time budget. Anthropic's September 2026 research post tested this setup. A single Claude model had one NVIDIA H200, 24 hours of wall time, accelerated builds of the kind section 4 links, a prompt of about 1,100 words and a reference sheet for the installed tools. It had no sub-agents. The post reports in silico binding scores comparable to those of an earlier campaign, which could use sub-agents and about 100 times as many GPU hours. These are predictor scores, not laboratory results.
Scale out by submitting each GPU step as a batch job to your Kubernetes or Slurm cluster (Route B). Claude Code runs wherever kubectl or sbatch runs. It writes and submits one job per tool per batch, reads the logs and result tables, and decides what to run next. The brief and the checks stay the same.
cluster/README.md describes what the cluster needs, gives an example Job manifest and lists the rules the session follows. We have documented this route, but it has not yet been run on a customer's own cluster. Move to it after Route A has proven your TOOLS.md.
4. Prerequisites
Access
Your organisation is approved under the program.
You belong to the group that holds the grant.
The program's model appears in the model selector on your surface.
Your declared use case covers this work (section 5).
In Claude Code, run /status to confirm the organisation. Then select the program's model with /model <id>.
Compute
For the first run, you need a machine that can run Claude Code and has:
one modern data-centre GPU with at least 40 GB of memory (smaller cards work with smaller batches, but take longer)
about 8 to 24 CPU cores
100 GB of disk for model weights and intermediate files
To scale out later (Route B), you need one of the following:
a Kubernetes namespace with a GPU node pool, where you can create Jobs, Pods and a PersistentVolumeClaim
a Slurm partition with GPUs
You do not need cluster-admin rights. cluster/README.md gives the exact requirements.
Software
Install the tools before the session starts, either on the machine (Route A) or in the container image your jobs use (Route B). Install each tool from its own repository, and check its licence against your organisation's policy.
| Group | Tools |
|---|---|
| Backbone generators | At least two of: RFdiffusion or a successor (RFdiffusion3, RFD4-Proteina), BindCraft, PXDesign, BoltzGen, Proteina-Complexa, the ESM cookbook's gradient-guided binder design through ESMFold2, or another open de novo binder generator your group trusts |
| Sequence design | ProteinMPNN or SolubleMPNN (the LigandMPNN code base) |
| Structure prediction for screening | At least two of: AlphaFold2-multimer (ColabFold), Boltz-2, Chai-1, ESMFold2, Protenix. Claude uses two during design. Ideally, hold back one or two more for the final check (section 9). |
| Analysis | TM-align or US-align, DockQ, DSSP, freesasa or another solvent-accessibility library, Biopython, and an ipSAE script (the interface predicted-aligned-error score of Dunbrack, 2025) |
Anthropic's September 2026 research post links to a public release of accelerated builds at github.com/anthropics/uplifting-biomolecular-modeling. The release has one kit per tool, 36 in all. The kits that matter here are:
Generators: RFdiffusion, RFdiffusion3, BindCraft (the
colabdesignkit), PXDesign, BoltzGen, Proteina-Complexa, Genie 3, mosaic and the ESM cookbook's gradient-guided binder design through ESMFold2Sequence design: ProteinMPNN, with its soluble weights
Structure prediction: ColabFold, Boltz-2, Chai-1, Protenix, OpenFold3 and ESMFold2, including ESMFold2's fast, alignment-conditioned and no-alignment variants
Interface scoring: AF2 initial guess
The release has no kit for RFD4-Proteina. Install that from its own repository, and read its model card.
Each kit runs its tool in a named mode. off is the unmodified tool. exact gives the same outputs, faster. fast is faster still, with small documented numeric differences. big uses the least GPU memory, for inputs the other modes cannot hold. Not every kit has all four, and with no mode named most kits run fast. Use the same mode for the controls and the candidates, and record it in TOOLS.md.
The kit code uses the Apache-2.0 licence. Each upstream tool keeps its own licence, which you will find in the kit's folder. Model weights are not part of the release. They come from their providers under the providers' own terms, which each kit's STOCK.md names. The release dates from 17 September 2026. It is published as-is and is not maintained, and it had not changed by 27 October 2026. Check each upstream licence as you would for the tool itself, and record the builds you use in your run notes.
Write a one-page TOOLS.md from TOOLS.md.example. It should say where the GPU work runs, how to call each tool, where the weights are and how much GPU memory each tool needs. Claude reads this file first and writes every tool call from it.
The plugin and the skill
In Claude Code, run
/plugin marketplace add anthropics/life-sciences.Run
/plugin install binder-gauntlet@life-sciences.Ask "which skills do you have?" and confirm that the list includes
binder-gauntlet.Run the skill's self-test once:
python3 ~/life-sciences/binder-gauntlet/scripts/sequence_profile.py --self-test.
Network
The run needs no network access from the tools. Fetch the target files (section 6) and model weights in advance. On a cluster, bake the weights into the image. The session itself still sends what it reads to the model service (section 10).
Time
| Task | Time |
|---|---|
| Tool installation (once, by your compute administrator) | Half a day to a day |
| First run on the public sample target, on one local GPU | About an hour of session time, or nearer two on a cluster, where each step waits to schedule |
| Controls and held-out check (within the session time above) | About one GPU-hour in total |
| Your own reading, scoring and hand checks | Two to three hours |
| A serious run on your own target | A working day of session time and a day of review |
5. Declared use case
Paste and adapt the statement in DECLARED-USE-CASE.md. In short:
Computational design and in-silico screening of de novo miniprotein binders against named protein targets in our discovery portfolio, by our protein-engineering and computational-biology staff, using open-source design and structure-prediction tools driven by the program's model on compute we control; public or our own target structures in, a scored and clustered design panel with a validation and developability dossier and a written rationale out; every panel reviewed by a protein scientist before anything is ordered or expressed; no toxins, no pathogen proteins, no patient data.
Make the statement specific to your actual targets and team. A specific statement makes monitoring simpler.
6. What you bring
| Input | Format | Notes | Required |
|---|---|---|---|
| Target domain sequence and boundaries | UniProt accession and residue range; FASTA | Use the exact construct you would express for an assay. Every score uses this chain, so decide it first. | Yes |
| Experimental structures containing the domain | mmCIF or PDB files from the Protein Data Bank | Include complexes with natural partners or existing binders if they exist. They show which surfaces are functional. They also supply the positive controls that the gauntlet runs through the same screen as your designs. | Yes |
| Reference panel for the checks | FASTA with a few sequences, each with its public source | Positives: the natural partner or a known binder, cut from a deposited complex. Negatives: a shuffled positive, one or two unrelated well-folded proteins of similar size, and one or two format-matched binders of other targets. Optional: the target's closest human paralogue and the mouse or cynomolgus orthologue, for specificity and cross-reactivity checks. sample/README.md lists the public PD-L1 sequences. backtests.md shows how they perform in the screen. | Recommended |
| Counter-target | Same as the target | Provide a close homologue that the binder should not bind, if selectivity matters. Claude refolds candidates against both (section 13). | Optional |
| Multiple-sequence alignment for the target | a3m | Some predictors score the target side better with an alignment. Build it in advance with the predictor's own tools. The binder side is always a designed sequence with no alignment. | Recommended |
TOOLS.md | Markdown, one page | States where the GPU work runs and how to call each tool (section 4). | Yes |
| What you already know | A few sentences in the prompt | Tell Claude which surface matters biologically, which epitopes your existing molecules cover, any length or composition limits from your expression system, and the intended format (bare binder, Fc fusion or tracer). | Optional |
On your first run, bring nothing of your own. Use the public sample target in sample/README.md: the IgV domain of human PD-L1 (UniProt Q9NZQ7, residues 18–132). The sample includes a small public reference panel and four public Protein Data Bank entries:
the domain alone
its complex with PD-1
its complex with an engineered high-affinity PD-1
its complex with a therapeutic antibody fragment
PD-L1 is a well-studied, rigid, single-domain target with a known functional face. This makes it a fair test of your setup and an easy case for the method. Your own targets will probably be harder.
7. Step by step
The prompts below are plain text. Use them unchanged on your first run. On later runs, change the target lines, the constraints and the budget, but keep the structure. The design brief is the same on both doors. Only the setup differs.
Route A: Claude Code on a GPU machine you control
Step 1. Install and select (5 minutes). In Claude Code, on the GPU machine, run:
/plugin marketplace add anthropics/life-sciences/plugin install binder-gauntlet@life-sciences/status, and confirm that the organisation is correct/model <program model id>
Step 2. Prepare the working folder and check the tools (10 to 20 minutes the first time). Most of this time goes to correcting TOOLS.md.
Create a working folder outside this repository and start Claude Code in it.
Add your
TOOLS.md, plus thetarget/andcontrols/folders that the fetch script insample/README.mdbuilds.Paste this setup check:
Before we start, check my setup. Confirm this folder holds target/ (with README.md, construct.fasta and at least one structure file), controls/ and a filled-in TOOLS.md, and list anything missing. Then run nvidia-smi and the smoke test TOOLS.md gives for each tool, one at a time. Show me a short table of the GPU and each tool (OK, or failed with the first error line), then stop.Wait until every tool in
TOOLS.mdhas responded on this machine before you continue.
Step 3. Give the design brief (about an hour of session time on one local GPU). Paste this brief:
I would like a panel of de novo miniprotein binder candidates against the target described in
target/README.md (human PD-L1, IgV domain, UniProt Q9NZQ7 residues 18-132; the structures in
target/ are public Protein Data Bank entries; controls/ holds a small public reference panel with
a README saying what each sequence is). TOOLS.md says where the GPU work runs and how each
installed tool is called; batch candidates so each tool run loads a model once, and keep every
script you write under jobs/ with its log. Plan for roughly two hours of my wall-clock time on
one GPU at a time (tell me if I may use more); keep your own eye on the time, and leave the
last fifteen minutes for tidying up and final checks.
Please work like this, and tell me briefly what you are doing as you go:
1. Look at the structures and choose a binding site. Say which surface you chose, which
residues, and why a binder there would do something useful.
2. Run the reference panel in controls/ through exactly the screen you will use for candidates,
first, and write the numbers to controls/reference-points.md, so every later number has
something to be read against.
3. Generate candidate backbones against the site with at least two different generators, and
design sequences onto them. Aim for a few hundred candidates of 50-120 residues.
4. Refold every candidate in complex with the target using two structure predictors. Keep a
candidate only if both are confident about the interface AND their refolded pose agrees with
your design model. Record the numbers per candidate.
5. Use the binder-gauntlet skill at every selection round, not just at the end: run its cheap
checks on the current shortlist and let them change what you keep, drop or redesign; keep a
running list of what you set aside and why.
6. Cluster the survivors by backbone shape and pick about thirty that cover as many clusters as
the scores allow. Check that no sequence is a close copy of the target itself or of anything
in the structures or controls I gave you.
7. Write designs.csv (one row per design: id, sequence, length, generator, site, each
predictor's interface confidence, pose agreement, cluster, one line of notes), one model file
per design under models/, report.md (the site and why, what you ran, how you chose and
steered the thirty, what the numbers do and do not mean, what a protein scientist should
verify before ordering anything), the gauntlet's dossier.md with its per-design CSV, and
the scripts you wrote under jobs/.
Save a first complete version of designs.csv, models/ and report.md early and keep them
current, so that if anything stops the session I still have a usable panel.Claude reads TOOLS.md and the structures, and reports the chosen site within a few minutes. It then runs the controls through the screen and starts the first generator batches. You do not need to watch.
Step 4. Read along, or come back later. If you read the transcript, look for the following:
Did the controls go through the screen before the candidates?
Did Claude notice disagreement between predictors, and what did it do about it?
Did the gauntlet's checks change a selection? For example, Claude might drop a candidate for a deamidation site in the interface, or redesign one with a hydrophobic free face. Or did Claude only write up the checks at the end?
Did Claude write the files early?
If Claude asks a question, answer it. Otherwise, let it work.
Step 5. Ask for the self-check when Claude says it has finished (5 minutes). Paste:
Before I read the panel: re-open designs.csv, report.md and dossier.md and check them against
what actually ran. For each design confirm the model file exists and the sequence in it matches
the row. List any number in report.md or dossier.md that you did not compute in this session,
and anything the dossier's "not checked" section is missing. Then tell me the three designs you
are least sure about and why.Step 6. Run the held-out check (about half a GPU-hour). Ask Claude to refold the final panel and the controls with the predictor you kept out of the session. Ask it to add the result to section 1 of the dossier as the independent check. Then drop any design that this check disputes.
Step 7. Score the run (two to three hours of your time).
Score the run with
rubric.mdParts 1 and 2.On the sample target, also score it against
sample/ground-truth.yaml, which covers site residues, control behaviour, the copy check and the planted note.Read the dossier against Part 3 of the rubric and
backtests.md§2.Complete the hand checks in section 9 before the panel goes anywhere.
Route B: Claude Code with GPU steps as batch jobs on your cluster
Complete Route A once first. Then run Claude Code where kubectl (with a context for your cluster) or sbatch (on a login node) runs. Make sure the image or environment described in cluster/README.md is in place.
Install and select, as in Route A step 1.
Prepare the working folder (15 to 30 minutes the first time). Follow Route A step 2, and fill in the Kubernetes or Slurm block of
TOOLS.md. On Slurm, use the shared filesystem. Ask Claude to read that block, set up the work volume (on Kubernetes), and submit one short test job that printsnvidia-smiand each tool's version, then show you the result and stop. Wait until the job has run on a GPU node and every tool has responded. Most of this step goes to finding out what your cluster calls its GPUs.Send the Route A brief unchanged.
TOOLS.mdalready says where the GPU work goes. Add "follow the rules in binder-gauntlet/cluster/README.md". Continue from Route A step 4, and expect the run to take nearer two hours, because each step waits to schedule.Clean up. Ask Claude to remove what it created for this run. It removes only objects that carry this run's labels, by name. It keeps the volume until you tell it otherwise.
8. What you get
You get the following files in the working folder. On Route B, Claude copies the tables and selected models back from the work volume as the run progresses.
| File | Contents |
|---|---|
designs.csv | One row per design: id, sequence, length, generator, site, a <predictor>_interface_confidence column for each predictor, pose_agreement (DockQ between the design model and each predictor's refold, or their mean), cluster and notes |
models/ | One PDB or mmCIF file per design, showing the designed complex as it came out of the pipeline, with binder and target as separate chains. These files are design models. They are not later predictions or experimental structures. |
report.md | The chosen site and the reasoning; the tools and settings used; the number of candidates generated, screened and kept at each stage; where the gauntlet's checks changed a decision; how the final panel was selected; the numbers and what they measure; and a list of items to verify by hand |
dossier.md and dossier.csv | The binder-gauntlet skill's validation dossier, plus one row per design and control, keyed by sequence so it joins to designs.csv. The format is in the skill's references/dossier-template.md. |
controls/reference-points.md | The control sequences' scores through your screen. Part 3 of rubric.md asks for this table. |
jobs/ | Every script Claude wrote for a GPU step, with its log (and on Kubernetes, the manifest it applied). Together with the session transcript, these files record what ran. Keep them with the outputs. |
The dossier has nine sections:
Binding evidence beyond the objective, with the controls' numbers beside the designs'
Function or blocker activity
Specificity and species cross-reactivity
Robustness
Native context
Developability per design
Interface metrics
Candidates set aside, and why
What was not checked, and why
9. What good looks like
This section summarises rubric.md.
The structures support the site choice. The report names residues that exist in the deposited entry and says what binding there would do. "A hydrophobic patch" is not a reason. "The face PD-1 engages in entry 4ZQK, so a binder there competes with PD-1" is a reason.
Every kept design passed at least two predictors and a pose-agreement check. The report shows the numbers per design and per predictor. A panel screened on one predictor inherits that predictor's blind spots.
The controls went through the identical screen first. Their numbers sit beside the panel's numbers in the dossier. If the screen cannot separate the target's known partner from a shuffled sequence, the panel's numbers tell you little.
The checks steered the run. The dossier's "set aside" section has entries. Claude dropped or redesigned some candidates mid-run because of an interface liability, a hydrophobic free face, a self-association hit or a failed monomer refold, and the report says so. If Claude wrote the dossier only after the final pick, the dossier says that too.
The panel is structurally varied. The report says how Claude measured variety. Thirty sequences on one backbone are one bet, not thirty.
No design is a copy. No design shares long stretches of sequence with the target, its natural partners or any binder in the structures or controls you supplied. The report says how Claude checked this. A wider novelty search is a hand check (see below).
The report describes each number accurately. Interface scores measure predictor confidence in a modelled interface. Developability numbers are descriptors shown against reference proteins, with no pass or fail where the literature gives no threshold. The report does not call any design a binder or rank designs by "affinity". The last section of the dossier lists what was not assessed.
The back-tests set your expectations. See backtests.md.
On PD-L1, a three-program screen gave these results:
It kept all thirteen public negatives below 0.25.
It found natural and engineered PD-1.
It missed the binding domains of three of the four marketed anti-PD-L1 antibodies tested.
It could not tell a micromolar partner from a picomolar one.
Expect designed helical miniproteins to score above real binders on this screen, because of how they are built.
For developability, §2 gives a public reference panel of small-protein drugs with computed descriptor ranges. It also names three things to catch in round one for helical de novo designs:
no tryptophan or tyrosine, which rules out an A280 measurement
deamidation-prone Asn and Asp motifs in the interface
alanine-rich stretches that read as hydrophobic on sequence scales
Read your own dossier against these results.
Check these by hand before anyone orders or expresses a design, or shows it outside the team:
Open several design models next to the target structure. Confirm that the binder sits on the claimed site with a plausible interface.
Search every sequence against public databases and your own collections for close matches to known proteins and existing binders of this target.
Read the dossier's developability table against your expression system's rules.
Read the "not checked" section against your own diligence list.
Confirm that the team applied the held-out predictor's verdict.
The designs that survive are candidates for expression and a binding assay. A qualified protein scientist decides what goes to the bench. The assay is the first point at which anyone can say that a design binds.
10. Data handling
What we send. The session sends the following to the model on your chosen surface, under your organisation's program terms:
your prompts
the files Claude opens or writes, including target files,
TOOLS.md, job scripts, result tables, the report and the dossierany job output that Claude reads
The design and prediction tools run on your own machine or cluster. They make no network calls once their weights are in place. On a cluster, the jobs need no egress. The work volume leaves the cluster only as the text and tables that the session reads back.
Where it is processed and how long it is kept. Processing takes place on Anthropic's first-party service, under the program's published terms.
Anthropic retains program usage for 30 days on every program surface.
Zero data retention is not available. Existing zero-retention or custom-retention agreements do not apply to usage under a grant.
Automated systems screen usage. People at Anthropic review flagged activity only, in rare circumstances.
Anthropic never uses program usage for model training or product improvement.
Anthropic monitors usage against your declared scope. If something looks out of scope, Anthropic notifies your admin and gives you one week to explain, narrow the scope or dispute it.
What stays with you. Claude writes every output file to your working folder or work volume, and writes nothing back to this repository. The machine or image, the weights, the volume and the jobs all remain yours. On a cluster, the session creates objects only in the namespace you name. It labels everything it creates, so that it can remove only those objects (cluster/README.md).
What is sensitive. On the first run, nothing is sensitive: the target is public and the designs are new sequences that belong to you. On your own targets, the target identity, the site and the designed sequences may all be confidential to your programme. Keep the work volume, the image registry and the outputs where such material is allowed. Remember that the transcript and the job logs contain this material too.
What not to send. Do not send:
patient-derived sequences or data
protected health information (PHI)
sequences or structures you do not have the right to process
anything outside your declared use case
During the beta, no Business Associate Agreement (BAA) covers the program. PHI workloads are therefore out of scope, and an organisation set up under a BAA cannot receive a grant.
11. Access level
De novo binder design against a human therapeutic target with open-source tools is mainstream discovery computational biology. It runs on the program's Standard Use grant. The closest published categories are:
"Drug and countermeasure discovery and preclinical support"
"Bioinformatics, computational biology, and research data infrastructure"
The program's launch post names basic science and R&D among the areas Standard Use serves. The use case your organisation declared and had approved decides whether your own work is in scope. Ask your program contact if you are unsure which category to use.
Run this work inside your program organisation with the program's model selected. Do not use a personal account or a non-program model. Outside a grant, the standard safeguards on biological research may decline protein-design sessions like this one.
This guide does not need the High-risk Use add-on. Toxins, pathogen proteins and anything your institution handles under enhanced containment are a different project. Ask your program contact before you declare such work, and do not run it under this guide's statement.
If the model declines a step that you believe your declared use case covers, do not rephrase the request to get around it. Talk to your program contact instead.
12. Troubleshooting
| Symptom | Likely cause | What to do |
|---|---|---|
| A generator or predictor crashes on start, or Claude cannot find it | The tool is not on the path, the weights are missing, or an expected scratch-directory or environment variable is unset | Update TOOLS.md with the exact working command and any environment variables. Make the tool check in step 2 run each tool's smallest example before the real session. Claude can usually work around failures that reach a log. It cannot work around silent ones. |
A tool from the accelerated release prints NOT ACTIVE and exits with code 3 | The kit's mode cannot start on this machine. A kit never falls back to the unmodified tool silently. | Read the reason on the NOT ACTIVE line. Most kits have a dry run, bash run.sh check, that shows what would start on this machine. Fix what the line names, or choose another mode and use it for the controls too. |
The accelerated ESMFold2 build, in fast mode, stops with a CUDA error ("illegal memory access" or "unspecified launch failure") part-way through a long list of inputs | Not documented. It has been seen in long-running fast-mode processes. The failure is loud: the process exits, and the inputs it had not finished have no output. | Re-run the inputs that were lost. To avoid it, fold fewer inputs per process, or set EF2_GRAPH_CAPTURE=0, which is slower. |
| The GPU runs out of memory, or everything slows down | Several tools are loaded at once, or batch sizes suit a larger card | Add the GPU's memory to TOOLS.md. Run one tool per run and batch inside the run. On small cards, drop the largest predictor from the in-session screen and use it only for the held-out check. |
| On a cluster, jobs stay Pending | No GPU node is free, your GPU pool needs a node selector or toleration, or your cluster names the GPU resource differently | Read the pending pod's Events lines, or ask Claude to describe the pod and read them to you. Fix the Kubernetes block of TOOLS.md. Ask your platform team what a GPU job in this namespace must carry. cluster/README.md covers more cases, including image pull errors, volume access modes and OOMKilled. |
| The skill never ran, or the dossier appeared only at the very end | The request did not name the skill, or the session treated it as a reporting template | Name the skill in the first message ("use the binder-gauntlet skill") and keep point 5 of the brief. A dossier written after the run still has value, and the skill says to label it that way. |
| The two predictors disagree on most candidates, or the panel is 30 near-identical bundles | Single-sequence and alignment-based predictors often disagree, or selection ranked on score alone | Keep only candidates that both predictors accept in the design pose, and report the disagreement rate. Ask for clustering by backbone shape with a cap per cluster, and ask Claude to state the number of distinct clusters. The held-out check in step 6 decides. |
| The model declines the design task or part of it | You are not on the program's model in the program organisation, the grant has not reached your group, or the work is outside your declaration | Do not rephrase to get around it. Check the surface, organisation, model and grant (section 11). Check that your declared use case names this kind of work and these targets. |
13. What's next
Your own target. Use the same brief with your construct, structures, reference panel and constraints. Run the controls first. If the screen cannot separate your target's known partner from a shuffled sequence, it will not tell you much about designs. If your known binders are antibodies, expect the screen to miss some of them (backtests.md §1).
Selectivity and species cross-reactivity. Add a counter-target (a close homologue the binder must avoid) and the orthologues your animal models need. Ask Claude to refold every shortlisted candidate against each one. The results go in section 3 of the dossier. Each extra chain adds roughly one screen's worth of Jobs.
More GPUs and longer sessions. The steps are independent, so several GPUs can run generators and predictors side by side, on one machine or as cluster jobs (Route B). You only need to change the budget sentence in the brief. A day of session time with interface redesign evens out the scores. Only experiments can show whether this produces better binders, so the checks matter even more as the search gets stronger.
Physics-based and licence-gated checks. Rosetta or FoldX energies and dedicated aggregation, solubility and T-cell-epitope predictors stay under "not checked" in the dossier until you add them to your image and TOOLS.md. The skill then uses them.
To the bench. Give the surviving panel, the report, the dossier, the models and the controls to the team that runs your expression and binding assays. Include the binding-dead mutant that the dossier names for each lead, as the assay's specificity control. Use the natural partner as a positive control. A yes or no binding readout is the first result that means anything.
License
Apache 2.0. See LICENSE.txt.
Requirements and compatibility
Written for: Claude Code, Claude apps
Works with: Claude Code, Claude apps, OpenAI Codex, GitHub Copilot, Cursor, Gemini CLI, Kiro, OpenCode, Goose, Amp, Roo Code, JetBrains Junie, Factory Droid, Devin (ex-Windsurf), Mistral Vibe, OpenHands, Letta
“Works with” means the tool reads the open Agent Skills format; a skill written for one tool may use features others lack.
Needs: Needs Python
The author says: Method-only skill. Part B's sequence checks run with the bundled script (python3, standard library only). Structure-based checks use whatever structure predictors and python structure libraries (biopython, freesasa, DSSP) the session has. No network access and no model calls.
Security
What our scanner noticed· Low risk
- Scripts that your agent may run
This skill includes scripts that your agent may run. Read them before you use it.
A static scan is not a guarantee. Skills are third-party content: review a skill before you let an agent use it.
Attribution and licence
- Published by
- Anthropic
- Publisher
- Anthropic (Official)
- Source
- anthropics/life-sciences · binder-gauntlet · commit 0d38fe5
- Licence
- Apache License 2.0 (redistribution allowed)
- ATTRIBUTION.md (written by AutoGineer)
- Synced
AutoGineer is not affiliated with or endorsed by Anthropic or Anthropic.
Download ZIP
The ZIP holds the skill’s files, its licence files and an ATTRIBUTION.md. Download binder-gauntlet.zip